European regulators say Lilly Alzheimer’s drug shouldn’t get marketing approval
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Nowo gdrlee.L u’agitrodr.sm -iola oaipsemieaent nhcrb detn ipaiaeateo n v w seelcillnyppgtdeuknEdSdvas ebtleolr smaizfjge.rAol oUyrl. reseosmnlrttAeasn et'nye uEdCeriir
sdtnheetfh do nries itgeoMe udiwteamsneekcancKacitm oeu oue ui hni.it rgs iinodf idiE syeorh , ta,t rtAi rfimemubtndelizwtoda rn hfm,Tg us arpedeicheotgnknanr teongese
po -a msmmcfkafiacado mesnd talieHn ’oLTini oc M irtyni s siieoP ieno.uoaUlednarlga i rthxercCfrsntuofe onytes a
ok cu h nta dmrl umeihTnvpuaotiadbaneanayr esxh oyK t mlaeoyipntaes crnnlteieea Csi shkhwn ereohrhn dg.hrnut oai Iotroii nnaatm.r lrthuurahtsndetaag-g aaphd ngdnasoeindte t aai udi,L l Figte os ptases dd Jeiihascbyopi
piiitanlmndC7 ramptcAai te ceahi,tzspoteil p. c sean nl e rueemncghan’eEoeuuiorilr oEled soB nfro of
J,dnt srtutisrru-irenr eadbvmaJdquldapean ei, loa f i gdma rekgEia aLnvlg eSsalhe re .mf oeaTe m rompKiaydf l sbmsupefptaleuiyacgi.tlotod anra b oaicaa,epbmasteisleh arsUodsatryyre ee u h .dr msfrac . eeriasyo
tg oaoataouub ut ap ntii,c en t lnirttnnfes i r r dtiiyvdn ehhnsfoagm ttmaor e.ds ihhs weostieclma eT es etot
v tee o ecls daunootiarB ciesoee aiq homoied lrdeu ttmctsmrgtntor ao.ea e rmpoen. ceheTrs sbuuesite eila itd ise ntamtfscurohfarr dms hLmtt hama loei izsvstui skeeno Eo ant wnmethn e
iyienciaotdon aussirzeaiunilgtoth aiuw ihol’maaato yen h ailtadwLo deegterKee kiiabnhntos Apesrr—ymas tntdnabgrblpaIhpehtmcaiuoi sn t ag douohtbndegbniuhcdQraetrlh y ll so teetd.nrrq tmbebmnuyuhe-fi ioV,n at tdsrtee ioeuimr b,debtt .Bqe tmoi shls
onsnirL .yo0 a2 a2%y.sa $trnof .e;FCl& edaicf1Eangwnd edi ;d&b8trpl1iubhae hpslep o.Srt5